Literature DB >> 1707749

(6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells.

G Pizzorno1, B A Moroson, A R Cashmore, G P Beardsley.   

Abstract

(6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid [(6R)DDATHF] is a folate antimetabolite with activity specifically directed against de novo purine synthesis, primarily through inhibition of glycinamide ribonucleotide transformylase. This inhibition resulted in major changes in the size of the nucleotide pools in CCRF-CEM cells. After a 4-h incubation with 1 microM (6R)DDATHF, dramatic reductions in the ATP and GTP pools were observed, with almost no effect on CTP, UTP, and deoxyribonucleotide pools. When the incubation was continued in drug-free medium, recovery of ATP and GTP pools was protracted. ATP did not return to normal until 24-36 h, and GTP pools were only partially repleted by 48 h. The ATP and GTP pools were not affected when the initial 4-h incubation with (6R)DDATHF was conducted in the presence of 100 microM hypoxanthine. Addition of hypoxanthine to the medium after a 4-h incubation with (6R)DDATHF caused rapid recovery of the ATP and GTP pools. Similar effects were seen when the purine precursor aminoimidazole carboxamide was used in place of hypoxanthine. The effect of (6R)DDATHF on nucleotide pools and the capability of hypoxanthine or aminoimidazole carboxamide to prevent or reverse this phenomenon correlated directly with the inhibition of cell growth. Presumably as a consequence of the decrease in purine nucleotide triphosphate levels, the conversion of exogenously added uridine, thymidine, and deoxyuridine to nucleotides was markedly decreased. These effects were protracted for almost 48 h and were also reversed by hypoxanthine. Differential repletion of ATP and GTP pools after (6R)DDATHF pre-treatment demonstrated that diminished precursor phosphorylation is primarily a consequence of GTP rather than ATP starvation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707749

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.

Authors:  Lei Wang; Adrianne Wallace; Sudhir Raghavan; Siobhan M Deis; Mike R Wilson; Si Yang; Lisa Polin; Kathryn White; Juiwanna Kushner; Steven Orr; Christina George; Carrie O'Connor; Zhanjun Hou; Shermaine Mitchell-Ryan; Charles E Dann; Larry H Matherly; Aleem Gangjee
Journal:  J Med Chem       Date:  2015-08-28       Impact factor: 7.446

2.  Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication.

Authors:  Yijin Wang; Wenshi Wang; Lei Xu; Xinying Zhou; Ehsan Shokrollahi; Krzysztof Felczak; Luc J W van der Laan; Krzysztof W Pankiewicz; Dave Sprengers; Nicolaas J H Raat; Herold J Metselaar; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Cancer cells activate p53 in response to 10-formyltetrahydrofolate dehydrogenase expression.

Authors:  Natalia V Oleinik; Natalia I Krupenko; David G Priest; Sergey A Krupenko
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

Review 4.  FDH: an aldehyde dehydrogenase fusion enzyme in folate metabolism.

Authors:  Sergey A Krupenko
Journal:  Chem Biol Interact       Date:  2008-09-19       Impact factor: 5.192

5.  Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes.

Authors:  Fausto J Rodriguez; Caterina Giannini; Yan W Asmann; Mukesh K Sharma; Arie Perry; Kathleen M Tibbetts; Robert B Jenkins; Bernd W Scheithauer; Shrikant Anant; Sarah Jenkins; Charles G Eberhart; Jann N Sarkaria; David H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2008-12       Impact factor: 3.685

6.  Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage.

Authors:  R N Turner; G W Aherne; N J Curtin
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.

Authors:  E Erba; S Sen; C Sessa; F L Vikhanskaya; M D'Incalci
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

8.  Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

Authors:  V J Chen; J R Bewley; S L Andis; R M Schultz; P W Iversen; C Shih; L G Mendelsohn; D E Seitz; J L Tonkinson
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.